Pociredir
Phase 1Small molecule
Pociredir is one of 39 small molecule programs targeting Sickle Cell Disease. It is currently in Phase 1.
1
Indications
3
Total Trials
2
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
272 competitors in Sickle Cell Disease
#DrugCompanyPhaseTrials
1Adakveo
NovartisPhase 3
Exjade
NovartisPhase 3
Brilinta
AstraZenecaPhase 3
Campath
GGenzyme, a Sanofi Company
Phase 3
Ritalin
NovartisPhase 3
Eliquis
Bristol-Myers SquibbPhase 3
Oxbryta
GGlobal Blood Therapeutics
Phase 3
Effient
CCosette Pharmaceuticals, Inc.
Phase 3
Endari
EEmmaus Medical, Inc.
Phase 3
Xarelto
WWim Janssens
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pociredir. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- FFulcrum Therapeutics